fludarabine has been researched along with thiazoles in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (64.29) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Joshi, SS; Pavletic, ZS; Wang, P | 1 |
| Broekhuizen, AJ; Hubeek, I; Kaspers, GJ; Peters, GJ | 1 |
| Ohnishi, K | 1 |
| Esser, R; Kalaäoui, RE; Klingebiel, T; Kloess, S; Koehl, U; Kreuter, J; Lehrnbecher, T; Munkelt, D; Schubert, R; Schwabe, D; Wehner, S; Zimmermann, SY | 1 |
| Hagist, S; Hallek, M; Krause, G; Pallasch, CP; Patz, M; Veldurthy, A; Wendtner, CM | 1 |
| Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
| Aloyz, R; Amrein, L; Ferrario, C; Gibson, SB; Hernandez, TA; Johnston, J; Panasci, L | 1 |
| Altavilla, G; Arrigo, C; Pitini, V | 1 |
| Forman, SJ; Kogut, NM; O'Donnell, MR; Palmer, JM; Senitzer, D; Slovak, ML; Snyder, DS; Spielberger, RT; Stein, AS; Thomas, SH; Tsai, NC | 1 |
| Horiike, S; Kobayashi, T; Kuroda, J; Matsumoto, Y; Mizutani, S; Ohshiro, M; Sasaki, N; Shimazaki, C; Shimura, Y; Taniwaki, M; Tsutsumi, Y; Uchiyama, H; Yamamoto, M | 1 |
| Bauer, K; Engert, A; Kluge, S; Kreuzer, KA; Monsef, I; Siebert, H; Skoetz, N | 1 |
| Beaumont, T; Breij, EC; Eldering, E; Elias, JA; Geest, CR; Kater, AP; Luijks, DM; Tromp, JM; van Laar, J; van Oers, MH | 1 |
| Apperley, J; Foroni, L; Ibrahim, A; Marin, D; Milojkovic, D; Reid, A | 1 |
| Beckers, MM; Daenen, S; Doorduijn, JK; Doreen Te Raa, G; Eldering, E; Kater, AP; Lankheet, NA; Liu, RD; Luijks, DM; Slinger, E; Spiering, M; Tonino, SH; van Oers, MH | 1 |
2 review(s) available for fludarabine and thiazoles
| Article | Year |
|---|---|
[State of the art in the treatment of chronic leukemias].
Topics: Aged; Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; Survival Analysis; Thiazoles; Vidarabine | 2006 |
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
1 trial(s) available for fludarabine and thiazoles
| Article | Year |
|---|---|
Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Drug Administration Schedule; Fatigue; Female; Gene Expression Regulation, Leukemic; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Male; Middle Aged; Nausea; NF-kappa B; Pneumonia; Pyrimidines; Thiazoles; Thrombocytopenia; Treatment Outcome; Vidarabine | 2014 |
11 other study(ies) available for fludarabine and thiazoles
| Article | Year |
|---|---|
Increased apoptosis in B-chronic lymphocytic leukemia cells as a result of cyclin D3 down regulation.
Topics: Annexin A5; Apoptosis; Apoptosis Regulatory Proteins; Caenorhabditis elegans Proteins; Cell Cycle; Cell Division; Cell Line, Tumor; Coloring Agents; Cyclin D3; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinases; Cyclins; Down-Regulation; Fluorescein-5-isothiocyanate; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Oligonucleotides, Antisense; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; Tetrazolium Salts; Thiazoles; Vidarabine | 2002 |
Modulation of cytarabine induced cytotoxicity using novel deoxynucleoside analogs in the HL60 cell line.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Line, Tumor; Cladribine; Coloring Agents; Cytarabine; Deoxycytidine; DNA; Gemcitabine; HL-60 Cells; Humans; Inhibitory Concentration 50; Nucleosides; Tetrazolium Salts; Thiazoles; Vidarabine | 2004 |
Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patients.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Busulfan; Caspase 3; Cell Line, Tumor; Child; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Killer Cells, Natural; Leukemia; Stem Cells; T-Lymphocytes; Tetrazolium Salts; Thiazoles; Vidarabine | 2008 |
The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes.
Topics: bcl-X Protein; Caspases; Dasatinib; Dose-Response Relationship, Drug; Drug Synergism; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Kinetics; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloid Cell Leukemia Sequence 1 Protein; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Thiazoles; Tumor Cells, Cultured; Vidarabine | 2008 |
Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Survival; Chlorambucil; Cytotoxicity Tests, Immunologic; Dasatinib; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug Synergism; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Linear Models; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Statistics, Nonparametric; Thiazoles; Tumor Suppressor Protein p53; Vidarabine | 2008 |
Dasatinib induces a response in chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blood Cell Count; Dasatinib; Female; Fusion Proteins, bcr-abl; Hemorrhage; Humans; Imatinib Mesylate; Jejunal Diseases; Leukemia, Lymphocytic, Chronic, B-Cell; Liver Neoplasms; Magnetic Resonance Imaging; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Rituximab; src-Family Kinases; Thiazoles; Tomography, X-Ray Computed; Vidarabine | 2009 |
Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Dasatinib; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Humans; Imatinib Mesylate; Male; Melphalan; Middle Aged; Myeloablative Agonists; Neoplasms, Second Primary; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Reoperation; Retrospective Studies; Risk; Thiazoles; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2009 |
Allogenic bone marrow transplantation with fludarabine/busulfan16 conditioning regimen and dasatinib maintenance therapy for elderly Philadelphia-positive acute/advanced leukemia patients.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Chemotherapy, Adjuvant; Dasatinib; Humans; Immunosuppressive Agents; Leukemia; Male; Philadelphia Chromosome; Pyrimidines; Thiazoles; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2010 |
Twelfth biannual report of the Cochrane Haematological Malignancies Group--focus on tyrosine kinase inhibitors.
Topics: Adrenal Cortex Hormones; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Dasatinib; Diphosphonates; Disease-Free Survival; Epoetin Alfa; Erythropoietin; Evidence-Based Medicine; Gemtuzumab; Graft vs Host Disease; Hematologic Neoplasms; Hodgkin Disease; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Recombinant Proteins; Rituximab; Stem Cell Transplantation; Thiazoles; Treatment Outcome; Vidarabine | 2011 |
Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Biphenyl Compounds; CD40 Antigens; CD40 Ligand; Coculture Techniques; Dasatinib; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Mice; Middle Aged; Minor Histocompatibility Antigens; Myeloid Cell Leukemia Sequence 1 Protein; NF-kappa B; NIH 3T3 Cells; Nitrophenols; p38 Mitogen-Activated Protein Kinases; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Signal Transduction; Sulfonamides; Thiazoles; Tumor Cells, Cultured; Vidarabine | 2012 |
Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Dasatinib; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pyrimidines; Thiazoles; Treatment Outcome; Vidarabine | 2012 |